Publications by authors named "Andrea Garcia-Sandoval"
Background: MYC-driven lymphomas are a subset of B-cell lymphomas characterized by genetic alterations that dysregulate the expression of the MYC oncogene. When overexpressed, typically through chromosomal translocations, amplifications, or other mechanisms, MYC can drive uncontrolled cell growth and contribute to cancer development. MYC-driven lymphomas are described as aggressive entities which require intensive treatment approaches and can be associated with poor prognosis.
View Article and Find Full Text PDFArticle Synopsis
- R-CHOP immuno-chemotherapy is effective for treating diffuse large B-cell lymphoma (DLBCL), but a significant percentage (30-40%) of patients either don't respond or relapse.
- Researchers have identified the protein CYCLON as a key factor linked to disease progression and treatment resistance in DLBCL, establishing it as a potential predictor of poor outcomes.
- The study also highlights the interaction between CYCLON and NPM1, suggesting that their co-expression and specific locations within the cell could provide insights for developing more tailored treatment strategies for high-risk DLBCL patients.